FindTrial
Sign In

Study of SM-7338 in the treatment of bacterial meningitis

Study of SM-7338 in the treatment of bacterial meningitis

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221609
Enrollment
Unknown
Registered
2011-10-06
Start date
2011-10-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial meningitis

Interventions

investigational material(s) Generic name etc : SM-7338 INN of investigational material : meropenem Therapeutic category code : 613 Antibiotic preparations acting mainly on gram-positive, gram-negative

Sponsors

Dainippon Sumitomo Pharma Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Patients with clinical symptoms and findings in cerebrospinal fluid of bacterial meningitis - Inpatients

Exclusion criteria

Exclusion criteria: - Patients with history of hypersensitivity to carbapenem,penicillin or cephem antibiotic - Patients with severe hepatic function or renal function - Patients with epilepsia or history of epilepsia - Patients with treatment of sodium valproate

Design outcomes

Primary

MeasureTime frame
Clinical response At the point of end of treatment—

Secondary

MeasureTime frame
Microbiological response At the point of end of treatment and follow up—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026